Narrative updates are currently in beta.

Back to narrative

RNAi Therapies Will Ensure Worldwide Market Expansion

ALNY logo
ALNY
AnalystConsensusTarget
Not Invested
Published 08 Aug 2024

Update shared on04 Aug 2025

Fair value Increased 25%
Previous
AnalystConsensusTarget's Fair Value
US$424.64
4.3% overvalued intrinsic discount
14 Aug
US$442.73
Loading
1Y
68.5%
7D
1.8%

Upward revisions in Alnylam Pharmaceuticals’ net profit margin and revenue growth forecasts have driven a significant increase in the consensus analyst price target from $339.27 to $421.64.


What's in the News


  • Alnylam raised its full-year 2025 revenue guidance to $2.65 billion–$2.8 billion from the prior range of $2.05 billion–$2.25 billion.
  • The company was removed from multiple Russell value and small cap indexes.
  • The European Commission approved AMVUTTRA (vutrisiran) for adult patients with cardiomyopathy due to wild-type or hereditary transthyretin amyloidosis, expanding its indication.
  • Results from the HELIOS-B Phase 3 study for vutrisiran in ATTR amyloidosis with cardiomyopathy supported global approvals and will be presented at the Heart Failure 2025 Congress.
  • Shareholders approved changes to the company's certificate of incorporation to allow for officer exculpation.

Valuation Changes


Summary of Valuation Changes for Alnylam Pharmaceuticals

  • The Consensus Analyst Price Target has significantly risen from $339.27 to $421.64.
  • The Net Profit Margin for Alnylam Pharmaceuticals has significantly risen from 20.60% to 26.54%.
  • The Consensus Revenue Growth forecasts for Alnylam Pharmaceuticals has significantly risen from 33.5% per annum to 41.2% per annum.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.